WRITTEN BY Frederick W. Sabido, MBA; Editor: Frederick L.H. Sabido, MD, FACS
Welcome to The Wellness Ledger
A weekly health led newsletter grounded in evidence-based medicine along with prospective randomized controlled trials (RCTs) by medical specialists. Our goal is to help you make sense of complex scientific information and turn it into clear, evidenced based practices you can use to make better decisions about your health and wellness.
Your doctor has probably never prescribed sermorelin. Most have not heard of it. But right now, people are injecting it every night before bed, convinced it does what synthetic HGH does at a fraction of the risk.
They might be right.
Three studies with a combined conducted between 1992 and 1997 demonstrate the medical evidence.
TL;DR | MEDICAL TREND SNAPSHOT
Growth hormone declines 75% by age 60
The drop is gradual, starts in your 30s, and produces real symptoms: less muscle, more visceral fat, lower energy. Researchers call it somatopause. Most doctors do not treat it unless it crosses into clinical growth hormone deficiency.
Two therapies, two completely different strategies
Sermorelin is a peptide (amino acid chain) that signals your anterior pituitary to produce natural growth hormone, (nHGH). Synthetic HGH (sHGH) acts directly, bypassing the anterior pituitary entirely. That regulated-versus-unregulated difference is what defines their divergent safety profiles.
Promising mechanism of action
Three RCTs form the medical evidence base for sermorelin use. Within 4 months, men on average gained 1.26 kg lean mass.
CLINICAL BREAKDOWN | THE PITUITARY CONVERSATION
Here is something worth knowing about how your body manages growth hormone. It is not a tap left running. It is a conversation.
The hypothalamus sends a signal called GHRH (growth hormone releasing hormone) to the anterior pituitary. The anterior pituitary then releases growth hormone in short pulses. GH then tells the liver to produce IGF-1, the molecule that actually builds muscle, burns fat, and repairs tissue. When HGH and IGF-1 climb high enough, the hypothalamus releases somatostatin, a brake signal that shuts the whole process down until levels fall again. The cycle repeats throughout the day. This is known as negative feedback inhibition (regulation).
Pulsatile. Self-regulating. Precise by design.
Somatopause is what happens when the active physiology gets quieter with age. The hypothalamus sends fewer signals. The anterior pituitary produces less growth hormone and by age 60 has dropped to roughly 25% of what it was at 25. The symptoms are diffuse and easy to attribute to other causes: fatigue, body composition shifts, slower muscle recovery, visceral fat gain, brain fog, and joint pain as well. Most doctors will not order a GH panel unless you present with something more alarming.
Now. What happens when you try to change this from the outside.
Sermorelin is a peptide, a 29 amino acid chain taken from the terminal ends of the human growth hormone molecule, that mimics GHRH. It binds to the anterior pituitary's receptors and asks the anterior pituitary to produce HGH. The pituitary obliges. GH rises in a natural pulse over the next 12 hours. Then somatostatin fires, the brake engages, and GH production stops. The feedback loop stays intact. The body self-corrects. You cannot push sermorelin past physiological limits because the system that enforces those functions remain intact. This is important to note, as it enhances your body’s responses naturally.
Synthetic HGH cannot be regulated. It bypasses the anterior pituitary entirely and dumps HGH directly into the bloodstream. The hypothalamus detects a flood of GH and IGF-1 and fires maximum somatostatin. But somatostatin cannot eliminate synthetic HGH already circulating. The pituitary goes quiet. The tissue stays saturated. The natural pulsatile rhythm disappears.
The tap analogy.
Sermorelin knocks on the door and asks. The body opens the door briefly, lets through what it needs, and closes it again. Synthetic HGH breaks the door down, floods the hallway, and the person inside cannot stop it even if they want to.
The side effect profiles of these two therapies trace directly back to that architectural difference.
THE MEDICAL EVIDENCE | THREE TRIALS, ONE HONEST READING
Three randomized controlled trials provide the medical adult evidence base for sermorelin usage. All from the 1990s.
Here is what each one actually found.
Corpas et al., 1992
High-dose sermorelin raised HGH and IGF-1 in 68-year-old men to levels statistically matching healthy 26-year-olds. Fasting glucose was unchanged.
Caveat: 14 days proves biochemical response only. Body composition improvements could not be assessed in two weeks.
Vittone et al., 1997
Nightly GH pulses doubled. Two of six muscle strength tests improved. But systemic IGF-1 did not rise at all despite the GH increase.
Caveat: Once-nightly dosing doubles the pulsatile flow of HGH which may or may not be seen as an increase in serum IGF-1 levels, especially dependent on the time of day the blood is drawn.
Khorram et al., 1997
Men gained 1.26 kg lean mass. Insulin sensitivity improved. Only adverse event: transient hyperlipidemia, self-resolved.
Caveat: Strongest evidence for the successful male cohort..
SAFETY | WHY THE MECHANISM CHANGES THE RISK
Sermorelin's safety advantage is structural, not coincidental. Because the somatostatin brake stays on, the negative feedback inhibition is maintained. The body cannot be pushed into supraphysiologic HGH levels through sermorelin alone. The negative feedback loop prevents it. In all three RCTs, adverse events were very occasional: injection site redness, occasional facial flushing, and the one case of self-resolving hyperlipidemia. There was no edema, joint pain or insulin resistance.
Synthetic HGH tells a different story. The Endocrine Society's clinical guidelines report that 5 to 18% of patients on therapeutic HGH experience fluid-related side effects including edema, joint pain, and muscle aches . One double-blind study found 15% of patients developed clinically significant edema during a 12-month treatment period. Carpal tunnel syndrome occurred in roughly 2% of patients on carefully titrated therapeutic doses.
The insulin resistance risk with synthetic HGH deserves attention. Continuous non pulsatile HGH drives free fatty acid release from adipose tissue, which blocks insulin signaling. The Endocrine Society guidelines explicitly note that starting HGH in patients with existing glycemic dysfunction will likely require increasing dosages of antidiabetic medications.
The malignancy question is where people get anxious, and it deserves an answer.
At therapeutic doses titrated to keep IGF-1 within normal limits (100-175), current meta-analyses do not show a statistically significant increase in new cancers. But when IGF-1 exceeds two standard deviations above normal, epidemiological data shows hazard ratios of 1.31 for prostate cancer and 1.25 for breast cancer. That is not proof of causation, but is the reason oncologists treat IGF-1 monitoring as non-negotiable on HGH therapy, and it is the reason sermorelin's feedback-preserved mechanism offers a genuine safety advantage: it is structurally harder to breach that ceiling when the system that enforces it remains intact.
REGULATORY REALITY | THE 2008 WITHDRAWAL EXPLAINED
EMD Serono notified the FDA in 2008 that it was discontinuing production of Geref and requested withdrawal of approval. The FDA confirmed in a 2013 Federal Register ruling: this withdrawal was purely commercial. Market demand had collapsed as cheap synthetic recombinant HGH dominated. The drug was not pulled for safety. It was pulled because the demand disappeared.
That distinction mattered for compounding pharmacies. Because sermorelin had a prior FDA approval and a confirmed safety history, licensed 503A and 503B pharmacies could legally continue producing it by physician prescription. That pathway has remained open for over a decade.
Then in 2023 and 2024, the FDA moved 19 peptides to a restricted compounding list, citing immunogenicity concerns. Ipamorelin, CJC-1295, GHRP-2, and GHRP-6 were all banned. Sermorelin was not. Its prior FDA history placed it in a different legal category. As of 2026, it remains the only major growth hormone secretagogue still accessible through licensed US compounding pharmacies by physician prescription.
THE PROTOCOL | FOUR QUESTIONS TO ASK BEFORE STARTING
Sermorelin requires a prescription and physician monitoring. Below is a checklist for a productive conversation with a physician who actually monitors labs.
01
Am I a candidate based on actual blood work?
The evidence base is in aging adults with somatopause, meaning age-related GH decline with and without clinical pathology. If your IGF-1 is already at the upper range for your age, drawing a baseline IGF-1 level is advised
02
What is the monitoring protocol, and at what intervals?
The RCTs that support sermorelin all used lab monitoring throughout. Any prescriber who does not monitor IGF-1 levels and basic metabolic panels is not following the evidence.
WHAT WE DO NOT KNOW | THE HONEST LIMITS
We acknowledge that the longest sermorelin RCT in adults lasted 4 months and the published long-term safety data for this growth hormone deficiency therapy fits in a long-weekend read. There are no decade-long registries, no large cohort studies, or post-market surveillance studies comparable to what exists for synthetic HGH. Why? primarily because Geref® was discontinued for business reasons.
Editor’s Comment
As an experienced medical specialist in bio-identical hormone replacement, I endorse Sermorelin. I am currently treating dozens of patients who have completely changed their metabolic profile, increased their lean mass, decreased their visceral fat, and improved sleep quality as well as muscle recovery. They have even improved their cardiovascular function, decreasing their hypertension and insulin resistance with a decrease in HbgA1c.The short-term safety profile in trials is favorable. The clinical evidence is genuinely encouraging at the same time. For a skeptical 40-year-old wondering whether this conversation is worth having with their doctor, the answer is probably yes.
READER'S PULSE
Have you ever asked your doctor about your GH levels?
Growth hormone decline is one of the least-discussed aging processes in clinical practice. Most people only hear about it from wellness content, never from a physician. We want to know your experience.
Reply to this issue with one of the following:
SAVE THIS | THE SCREENSHOT SUMMARY
SOURCES
Corpas E, Harman SM, Blackman MR. "GH-releasing hormone-(1-29) twice daily reverses decreased GH and IGF-1 levels in old men." J Clin Endocrinol Metab. 1992;75(2):530-535. PMID: 1379256.
Vittone J, Blackman MR, et al. "Effects of single nightly injections of GHRH (1-29) in healthy elderly men." Metabolism. 1997;46(1):89-96. PMID: 9005976.
Khorram O, Laughlin GA, Yen SS. "Endocrine and metabolic effects of long-term administration of [Nle27]GHRH-(1-29)-NH2 in age-advanced men and women." J Clin Endocrinol Metab. 1997;82(5):1472-1479. PMID: 9141536.
Molitch ME, et al. "Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline." J Clin Endocrinol Metab. 2011;96(6):1587-1609.
Federal Register. "Determination That GEREF Was Not Withdrawn for Reasons of Safety or Effectiveness." March 4, 2013. Document 2013-04827.
PMC: Long-term Safety of GH in Adults. PMC9202689. N=15,809 GH-treated patients.
PMC: Growth Hormone and Aging. NCBI Bookshelf NBK279163.
The Wellness Ledger is for informational purposes only. It does not constitute medical advice. Consult a licensed physician before starting any hormonal therapy or intervention.
